Axol Bioscience

Powering advanced, more human-relevant in vitro disease models.

As drug discovery continues to explore more human-relevant approaches to disease modeling, human iPSC technology is gaining momentum. Using this technology, consented blood or skin donations from patients and healthy donors are ‘reprogrammed’ into a stem cell state, from which they can be turned into any cell type including neurons, neuroinflammatory cells, muscle cells and cardiac cells.

iPSC-derived cells can then be grown on their own (‘monocultures) or in mixtures (‘co-cultures’) of different cell types to make advanced in vitro models for research, toxicity studies and drug discovery. These models can be used to test compounds for safety and effectiveness.

High-quality iPSC-derived cells can be used to fuel robust, scalable in vitro human disease models to accelerate and de-risk drug discovery. 

At Axol Bioscience, they have spent the past decade developing the manufacturing capabilities to produce high-quality, functional iPSC-derived cells with excellent consistency. Your research can benefit from their quality-focused approach, with their catalog of robust, highly relevant iPSC-derived neurons and cardiomyocytes developed at their ISO 9001:2015-accredited production facility.

Their leading axoCells^TM cell types include:

• Neurons: Cortical excitatory neurons, striatal neurons, cortical inhibitory interneurons, sensory neurons, motor neurons
• Neuroinflammatory cells: Microglia, astrocytes
• Cardiomyocytes: Atrial cardiomyocytes, ventricular cardiomyocytes
• Muscle cells: Myotubes

Their iPSC-derived cells have been specifically developed to fuel advanced in vitro systems for drug discovery and drug safety.

They provide functional cells to explore:

• Neuroscience: modeling neurodegenerative and neuroinflammatory diseases including ALS, Alzheimer’s disease and Huntington’s Disease
• Pain and sensation: modeling pain and sensory function for drug discovery and neurotoxicity testing
• Cardiovascular: using functional cardiomyocytes to model cardiac diseases (including arrhythmias) and for cardiotoxicity screening